Doxy-PEP does not work equally against the three infections it targets, and averaging them into a single figure hides the most useful part of the picture. The trials consistently found a large effect against chlamydia and syphilis and a much smaller one against gonorrhoea.
Chlamydia
The strongest result. Trials found reductions in the region of ninety per cent among participants using doxy-PEP consistently. Chlamydia trachomatis has remained highly susceptible to tetracyclines, which is also why doxycycline is the first-line treatment for it in the UK. There is no meaningful resistance problem to work around.
Syphilis
Similarly strong, with reductions around ninety per cent reported. Treponema pallidum, the bacterium causing syphilis, has shown no significant tetracycline resistance, and doxycycline is an established alternative treatment for people allergic to penicillin. Given that syphilis rates in the UK have risen substantially and that the initial sore is frequently painless and internal, this is arguably the most valuable part of the effect.
Gonorrhoea
Considerably weaker, with reductions of roughly half reported in the main trial and less in some analyses. The explanation is straightforward: tetracycline resistance in Neisseria gonorrhoeae is already common, and in many settings the majority of circulating strains carry it. Where resistance is more prevalent, the effect is smaller. This matters in the UK, where gonorrhoea is the more common of the bacterial infections in men who have sex with men.
Does it work at every site?
The trials measured infections at urethral, rectal and pharyngeal sites and found benefit across them, though the gonorrhoea effect at the throat was the weakest of all. Pharyngeal gonorrhoea is difficult to treat as well as to prevent, because antibiotic concentrations in throat tissue are lower.
Why did the trial in women not show benefit?
A study in cisgender women in Kenya found no significant reduction. Proposed explanations include lower adherence measured by drug levels, and differences in how doxycycline penetrates vaginal tissue compared with rectal tissue. This is unresolved, and it is why current recommendations focus on the populations where the effect has been demonstrated.
How does adherence affect the figures?
As with every prophylaxis, headline figures reflect people who took it. Analyses restricted to participants with detectable drug levels showed larger effects than intention-to-treat figures. Taking the dose within the recommended window after each condomless encounter is what produces the protection, and taking it occasionally produces occasional protection.
What does this mean practically?
If your main concern is syphilis or repeated chlamydia, doxy-PEP addresses that well. If your main concern is gonorrhoea, it helps somewhat but is not the answer, and the meningococcal B vaccine where available plus regular screening does more. Understanding which infection you actually keep getting is worth knowing before deciding whether this is useful for you.
What it does not touch
HIV, herpes, HPV, hepatitis A, B and C, mpox, and Mycoplasma genitalium in any reliable way. PrEP, vaccination and screening cover those, and doxy-PEP does not reduce the need for any of them.
How were these figures measured?
By comparing infection rates in people randomised to take doxycycline after sex against those receiving standard care, with participants screened regularly at all three sites rather than only when symptomatic. That matters, because a great many of the infections counted were silent ones that would never have been noticed otherwise. The figures therefore describe infections detected by screening rather than illnesses avoided.
Does it work if you already have an infection?
No, and taking it in that situation is counterproductive. A single dose can partially suppress an established infection without curing it, which can make a subsequent test unreliable while leaving you infected. If you know you have something untreated, get proper treatment first.
What about repeat infections in the same year?
The trials found the effect held across multiple exposures rather than diminishing, which is what you would expect given there is no immunity involved either way. Someone acquiring several infections a year is the group where the absolute benefit is largest.
What figure should you carry?
Roughly nine in ten for chlamydia and syphilis, roughly one in two at best for gonorrhoea, nothing for everything else.